Page 117 - 《中国药科大学学报》2025年第4期

第 56 卷第 4 期 李海岚，等：中药活性成分调节脂质代谢改善代谢功能障碍相关脂肪性肝病的研究进展 513

(MASLD): Beyond insulin resistance[J]. J Hepatol, 2023, 2023, 77(1): 73-86.
79(6): 1524-1541. [19] Yu MY, Alimujiang M, Hu LL, et al. Berberine alleviates lipid
[3] Mosca A, Manco M, Braghini MR, et al. Environment, en- metabolism disorders via inhibition of mitochondrial complex I
docrine disruptors, and fatty liver disease associated with in gut and liver[J]. Int J Biol Sci, 2021, 17(7): 1693-1707.
metabolic dysfunction (MASLD)[J]. Metabolites, 2024, 14(1): [20] Nie KX, Gao Y, Chen S, et al. Diosgenin attenuates non-alco-
71. holic fatty liver disease in type 2 diabetes through regulating
[4] Li YX, Yang PP, Ye JL, et al. Updated mechanisms of MASLD SIRT6-related fatty acid uptake[J]. Phytomedicine, 2023, 111:
pathogenesis[J]. Lipids Health Dis, 2024, 23(1): 117. 154661.
[5] Geng YN, Faber KN, de Meijer VE, et al. How does hepatic [21] Zhao ZH, Deng ZT, Huang SL, et al. Alisol B alleviates hepato-
lipid accumulation lead to lipotoxicity in non-alcoholic fatty liv- cyte lipid accumulation and lipotoxicity via regulating RARα-
er disease[J]? Hepatol Int, 2021, 15(1): 21-35. PPARγ-CD36 cascade and attenuates non-alcoholic steatohep-
[6] Gluchowski NL, Becuwe M, Walther TC, et al. Lipid droplets atitis in mice[J]. Nutrients, 2022, 14(12): 2411.
and liver disease: from basic biology to clinical implications[J]. [22] Gao Y, Zhang SJ, Li JJ, et al. Effect and mechanism of ginseno-
Nat Rev Gastroenterol Hepatol, 2017, 14(6): 343-355. side Rg1-regulating hepatic steatosis in HepG2 cells induced by
[7] Li YX, Huang XG, Yang G, et al. CD36 favours fat sensing and free fatty acid[J]. Biosci Biotechnol Biochem, 2020, 84(11):
transport to govern lipid metabolism[J]. Prog Lipid Res, 2022, 2228-2240.
88: 101193. [23] Shen BY, Zhao CX, Wang Y, et al. Aucubin inhibited lipid ac-
[8] Qiu PS, Wang HZ, Zhang MN, et al. FATP2-targeted therapies cumulation and oxidative stress via Nrf2/HO-1 and AMPK sig-
- A role beyond fatty liver disease[J]. Pharmacol Res, 2020, nalling pathways[J]. J Cell Mol Med, 2019, 23(6): 4063-4075.
161: 105228. [24] Syed-Abdul MM. Lipid metabolism in metabolic-associated
[9] Enooku K, Tsutsumi T, Kondo M, et al. Hepatic FATP5 expres- steatotic liver disease (MASLD)[J]. Metabolites, 2023, 14(1):
sion is associated with histological progression and loss of hep- 12.
atic fat in NAFLD patients[J]. J Gastroenterol, 2020, 55(2): [25] Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mecha-
227-243. nisms of hepatic lipid accumulation in non-alcoholic fatty liver
[10] Kumari A, Pal Pathak D, Asthana S. Bile acids mediated poten- disease[J]. Cell Mol Life Sci, 2018, 75(18): 3313-3327.
tial functional interaction between FXR and FATP5 in the regu- [26] Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic
lation of Lipid Metabolism[J]. Int J Biol Sci, 2020, 16(13): liver disease and liver cancer[J]. JHEP Rep, 2022, 4(6): 100479.
2308-2322. [27] Wang CC, Tong Y, Wen YK, et al. Hepatocellular carcinoma-
[11] Li HL, Wu XP, Xu AM, et al. A-FABP in metabolic diseases associated protein TD26 interacts and enhances sterol regulato-
and the therapeutic implications: an update[J]. Int J Mol Sci, ry element-binding protein 1 activity to promote tumor cell pro-
2021, 22(17): 9386. liferation and growth[J]. Hepatology, 2018, 68(5): 1833-1850.
[12] Zhang XH, Zhang YZ, Gao W, et al. Naringin improves lipid [28] Zeng H, Qin H, Liao M, et al. CD36 promotes de novo lipogen-
metabolism in a tissue-engineered liver model of NAFLD and esis in hepatocytes through INSIG2-dependent SREBP1 pro-
the underlying mechanisms[J]. Life Sci, 2021, 277: 119487. cessing[J]. Mol Metab, 2022, 57: 101428.
[13] Yang JS, Tongson J, Kim KH, et al. Piceatannol attenuates fat [29] Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance
accumulation and oxidative stress in steatosis-induced HepG2 drives hepatic de novo lipogenesis in nonalcoholic fatty liver
cells[J]. Curr Res Food Sci, 2020, 3: 92-99. disease[J]. J Clin Invest, 2020, 130(3): 1453-1460.
[14] Li YL, Jiang WD, Feng Y, et al. Betaine alleviates high-fat diet- [30] Régnier M, Carbinatti T, Parlati L, et al. The role of ChREBP in
induced disruptionof hepatic lipid and iron homeostasis in carbohydrate sensing and NAFLD development[J]. Nat Rev En-
mice[J]. Int J Mol Sci, 2022, 23(11): 6263. docrinol, 2023, 19(6): 336-349.
[15] Meng LC, Zheng JY, Qiu YH, et al. Salvianolic acid B amelio- [31] Li K, Zhang KN, Wang H, et al. Hrd1-mediated ACLY ubiqui-
rates non-alcoholic fatty liver disease by inhibiting hepatic lipid tination alleviate NAFLD in db/db mice[J]. Metabolism, 2021,
accumulation and NLRP3 inflammasome in ob/ob mice[J]. Int 114: 154349.
Immunopharmacol, 2022, 111: 109099. [32] Morrow MR, Batchuluun B, Wu JH, et al. Inhibition of ATP-
[16] Xu H, Chen GF, Ma YS, et al. Hepatic proteomic changes and citrate lyase improves NASH, liver fibrosis, and
Sirt1/AMPK signaling activation by oxymatrine treatment in dyslipidemia[J]. Cell Metab, 2022, 34(6): 919-936. e8.
rats with non-alcoholic steatosis[J]. Front Pharmacol, 2020, 11: [33] Yang LY, Liu QQ, Zhang H, et al. Silibinin improves nonalco-
216. holic fatty liver by regulating the expression of miR-122: an in
[17] Suguro R, Pang XC, Yuan ZW, et al. Combinational applicaton vitro and in vivo study[J]. Mol Med Rep, 2021, 23(5): 335.
of silybin and tangeretin attenuates the progression of non-alco- [34] Wang MY, Zhang SS, An MF, et al. Neferine ameliorates non-
holic steatohepatitis (NASH) in mice via modulating lipid alcoholic steatohepatitis through regulating AMPK pathway[J].
metabolism[J]. Pharmacol Res, 2020, 151: 104519. Phytomedicine, 2023, 114: 154798.
[18] Ran LS, Wu YZ, Gan YW, et al. Andrographolide ameliorates [35] Hu ML, Zhang DR, Xu HY, et al. Salidroside activates the
hepatic steatosis by suppressing FATP2-mediated fatty acid up- AMP-activated protein kinase pathway to suppress nonalco-
take in mice with nonalcoholic fatty liver disease[J]. J Nat Med, holic steatohepatitis in mice[J]. Hepatology, 2021, 74(6): 3056-